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Abstract
The discovery of a family of membrane water channel proteins called aquaporins, and the finding that aquaporin
1 was located in the choroid plexus, has prompted interest in the role of aquaporins in cerebrospinal fluid (CSF)
production and consequently hydrocephalus. While the role of aquaporin 1 in choroidal CSF production has been
demonstrated, the relevance of aquaporin 1 to the pathophysiology of hydrocephalus remains debated. This has
been further hampered by the lack of a non-toxic specific pharmacological blocking agent for aquaporin 1. In recent
times aquaporin 4, the most abundant aquaporin within the brain itself, which has also been shown to have a role in
brain water physiology and relevance to brain oedema in trauma and tumours, has become an alternative focus of
attention for hydrocephalus research. This review summarises current knowledge and concepts in relation to aqua-
porins, specifically aquaporin 1 and 4, and hydrocephalus. It also examines the relevance of aquaporins as potential
therapeutic targets in hydrocephalus and other CSF circulation disorders.
Introduction
Aquaporins are a family of integral membrane proteins
that function as water channels. The existence of such
water channels had been postulated for some time as
the passage of water across certain membranes is too
rapid to be explained on the basis of diffusion through
plasma membranes [1]. The identification of AQP1[2],
initially named CHIP28 [3], was later followed by the
identification of 12 other aquaporins. Aquaporins are
distributed widely throughout the body but notably in
the kidney, red blood cells, lung and secretory epithelia
such as the salivary glands [1].
There are two main aquaporins within the CNS: AQP1
and 4 (Figure 1). AQP1 is found in the apical membrane
of the choroid plexus [4,5] (Figure 2). It appears shortly
after the choroid plexus in embryonic development [6]
and is localised to the apical membrane. With ageing,
choroidal AQP1 levels may be reduced [7]. AQP1 is also
found in other organs such as red blood cells, salivary
glands, cardiac muscle and kidneys. These findings
appear consistent across species, but recently Arciénaga
et al. [8] have demonstrated a more widespread distribu-
tion of AQP1 in non-human primates including white
matter astrocytes, Schwann cells along oculomotor and
trigeminal nerves as well as in neurons on the surface of
pial blood vessels. AQP4 is located in the astrocyte foot
processes that surround capillaries in the CNS as well as
along the basolateral membrane of the ventricular epen-
dymal cells. Its distribution appears consistent across
species. A third aquaporin, AQP9, is also found within
the CNS but is limited to small populations of catechola-
minergic neurons as well as in astrocytes in cortical grey
matter and hippocampus [8,9]. AQP9, being an aquagly-
ceroporin, also transports glycerol, lactate and other
molecules [10,11]. It has been proposed to have a role in
regulation of energy metabolism in the brain [12].
Naturally, the identification of a water channel protein
in the apical membrane of the choroid plexus epithe-
lium has generated interest in its role in CSF produc-
tion, and consequently CSF circulation disorders. While
AQP1 does appear to contribute to CSF production, its
role in the pathophysiology of hydrocephalus has not
been well studied and remains unclear. Studies demon-
strating a role for AQP4 in relation to brain oedema in
tumours, trauma and stroke as well as the observation
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hydrocephalus, has also generated interest in the role of
AQP4 in CSF circulation disorders.
There is no doubt that treatments for hydrocephalus
and other CSF circulation disorders could be improved.
Developing new technologies and improving CSF shunts
and surgical procedures is important. However, more sub-
stantial improvements in the treatment of hydrocephalus
are likely to be achieved by advancing knowledge of CSF
physiology in health and disease [13]. Molecules such as
aquaporins are an avenue of research through which the
latter may be achieved. This review summarises current
knowledge and concepts of CSF physiology and CSF circu-
lation disorders as they relate to aquaporins. Strategies
to further examine aquaporins in CSF circulation disor-
ders are suggested.
Aquaporin 1
AQP1 and CSF production
CSF production has choroidal and extrachoroidal com-
ponents. Choroidal CSF secretion relies on the active
production of an osmotic gradient. This osmotic gradi-
ent is driven mainly by carbonic anhydrase and Na
+/K
+
ATPase. For a review of CSF production see Johanson
Figure 1 Distribution in brain of aquaporin-1 (AQP1, blue) and AQP4 (orange), schematically illustrated on a sagittal section of a
human brain. a: AQP4 occurs in the basolateral membrane of ependymal cells. b: AQP1 is expressed at the apical membrane of choroid plexus
epithelial cells. c: AQP4 is concentrated in astrocytic end-feet, specifically in those membrane domains that abut on brain capillaries or on pia. d:
AQP4 is expressed in glial lamellae of the supraoptic nucleus and other osmosensitive regions. AQP4 also occurs in non end-feet membranes of
astrocytes, but at comparatively low concentrations. In the neocortex, AQP4 expression in non end-feet membranes increases from deep to
superficial layers. The cerebellum shows the opposite gradient, with higher concentrations in the granule cell layer than in the molecular layer.
Reprinted with permission from [20].
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allows water to follow the osmotic gradient. AQP1 is
important in maintaining this osmotic permeability of
the apical membrane which is reduced by 4.8-fold in
AQP1-null mice [15]. Only one study [15] has examined
the role of AQP1 in CSF production and maintenance
of intracranial pressure. In AQP1-null mice, CSF pro-
duction was approximately 20% less than in wild-type
mice (0.38 ± 0.02 vs. 0.30 ± 0.01 μl min
-1). CSF pressure
was also 56% lower in AQP1-null mice (9.5 ± 1.4 vs. 4.2
±0 . 4c mH 2O) which may have been contributed to,
but was not fully explained by, a lower central venous
pressure in these mice. While apical AQP1 is well
placed to significantly contribute to CSF production,
how the passage of water across the basolateral mem-
brane is facilitated is not clear. There are reports of
AQP1 being identified in the basolateral membrane of
choroid plexus epithelium [5,16] but it is relatively
scarce.
AQP1 in hydrocephalus
Understanding the response of AQP1 to changes in CSF
pressure and, in particular hydrocephalus, is important
for determining a possible therapeutic potential. If
AQP1 expression was to be significantly down-regulated
in hydrocephalus, its therapeutic potential would be lim-
ited. However, if it remained unchanged or even were
increased then pharmacological blockade might result in
a therapeutically beneficial reduction in CSF production.
Mao et al. [17] examined AQP1 in response to cisternal
kaolin-induced hydrocephalus in the rat. In this chronic
model of hydrocephalus, AQP1 protein and mRNA
were unchanged compared to controls at 4 weeks and at
9 months after induction of hydrocephalus. However, in
this study the choroid plexus was not studied separately;
instead whole brain lysates were studied.
We have studied AQP1 expression and localisation in
the choroid plexus of hydrocephalic adult mice using a
cisternal kaolin injection model (Owler et al,u n p u b -
lished data). We have found that AQP1 protein is
unchanged compared to saline injected controls at 3
and 5 days post-injection of kaolin using Western Blot
analysis of choroid plexus tissue. AQP1 mRNA levels
were lower in hydrocephalic mice at 3 days post-kaolin
injection but unchanged compared to saline-injected
controls at 5 days post-kaolin. There is no clear expla-
nation for this finding. In may be a reflection of an early
and temporary reduction in AQP1 transcription in
response to hydrocephalus. This needs to be clarified by
further studies in other models of hydrocephalus.
While there appeared to be no change in the overall
level of AQP 1 protein, immunohistochemistry staining
for AQP 1 in choroid plexus specimens suggested that
there was AQP1 staining in the cytoplasm of kaolin-
injected mice compared to saline-injected controls. This
was further studied using immuno-gold electron micro-
scopy. We were able to confirm AQP1 gold labelling
within the cytoplasm of choroid plexus epithelial cells
which was absent in control mice (Figure 4). Further-
more this gold-labelling was also associated with endo-
somes and lysosomes. There was also gold-labelling of
AQP1 along the basolateral membrane. The changes in
AQP1 localisation were associated with other ultrastruc-
tural changes (Figure 5) reported by other authors in
relation to the choroid plexus in hydrocephalus [18].
Such ultrastructural changes include a reduction in the
number of microvilli which become shorter and swollen,
the appearance in the cytoplasm of primary and second-
ary endosomes and lysosomes within the cytoplasm as
well as the appearance of intercellular clefts. Despite the
appearance of the latter, tight junctions at the apical
membrane remained intact. Apoptosis was not present
in our study or those of others [18]. The association of
these changes, particularly those of the microvilli, with
Figure 2 AQP1 localisation in choroid plexus epithelial cell in
wild-type mice. Mouse coronal paraffin sections were incubated
with rabbit anti-AQP1 antibody at 4°C overnight followed by
incubation of anti-rabbit Ig conjugated with biotin and standard
ABC technique (A and B) or anti-rabbit Ig conjugated with Alexa
488 (C). Positive staining for AQP1 is on the apical surface of the
epithelial cells of normal wild-type mice. Panel B is the high
magnification image of panel A. (Owler et al, unpublished data)
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the question of whether the changes in AQP1 localisa-
tion are a reflection of ultrastructural alterations or
whether they reflect a compensatory mechanism for
hydrocephalus, or both.
Therapeutic potential of AQP1
The findings reported above may suggest that AQP1 is
not a therapeutic target for management as AQP1 is
internalised in response to hydrocephalus. Internalisation
of AQP1 clearly renders it non-functional in terms of
CSF production. However, we are of the opinion that
AQP1 is still important as a possible therapeutic target
for two reasons. Firstly, a large proportion of AQP1
remains in the apical membrane in response to hydroce-
phalus and therefore must still contribute to CSF produc-
tion even in the face of hydrocephalus. Secondly, we
found that AQP1-null mice do not develop hydrocepha-
lus, or at least, the degree of ventricular dilation achieved
in the cisternal kaolin-injection model, is much less than
that in wild-type mice (Figure 6).
W h i l et h e r ea r es o m es t u d i e so fA Q P 1i ne x p e r i m e n -
tal hydrocephalus, there is a paucity of human data in
relation to aquaporins and hydrocephalus. Longatti et al
[19] reported AQP1 immunostaining in nine choroid
plexus tumours and found that staining patterns varied
between individual tumours. Only in one case was there
communicating hydrocephalus and this patient’s tumour
had strong AQP1 staining. We are currently in the pro-
cess of accumulating choroid plexus specimens from
patients with and without hydrocephalus to determine
whether our observations in experimental hydrocephalus
translate into the clinical environment.
Regulation of AQP1
Regulation of AQP1 may occur through several mechan-
isms. First, the function may be altered by various com-
pounds or biological processes. Second, because the
Figure 4 Immuno-gold electron micrograph of choroid plexus
epithelial cell from a wild type mouse after cisternal kaolin
injection. There is gold labelling (arrows) of AQP1 within the
cytoplasm and a lysosome. (Owler et al, unpublished data).
Figure 3 Ion transporters and channels in mammalian choroidal epithelium. CSF secretion results from coordinated transport of ions and
water from basolateral membrane to cytoplasm, then sequentially across apical membrane into ventricles. On the plasma-facing membrane is
parallel Na
+-H
+ and Cl
--HCO3
- exchange bringing Na
+ and Cl
- into cells in exchange for H
+ and HCO3
-, respectively. Also basolaterally located is
Na
+-HCO3
- cotransport (NBCn1) and Na-dependent Cl
--HCO3
- exchange that modulate pH and perhaps CSF formation. Apical Na
+ pumping
maintains a low cell Na
+ that sets up a favorable basolateral gradient to drive Na
+ uptake. Na
+ is extruded into CSF mainly via the Na
+ pump and,
under some conditions, the Na
+-K
+-2Cl
- cotransporter. K
+-Cl
- cotransport helps maintain cell volume. Apical channels facilitate K
+,C l
- and HCO3
-
diffusion into CSF. Aquaporin 1 (AQP1) channels on CSF-facing membrane mediate water flux into ventricles. Polarized distribution of carbonic
anhydrase (c.a.) and Na
+-K
+-ATPase, and aquaporins, enable net ion and water translocation to CSF. Reprinted with permission from [14].
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apical membrane of the choroid plexus, AQP1 may be
regulated by changes in its location within the cell.
Finally, the overall level of AQP1 protein may be regu-
lated in response to various physiological or pathophy-
siological parameters. There is some evidence for each
of these mechanisms although the details remain
unclear. In relation to regulation of AQP1 function and
permeability, it is well known that mercurial compounds
inhibit AQP1 [20]. The human binding site for Hg
2+ is
Cys189 [21]. Phosphorylation of AQP1 may influence
AQP1 function and water permeability [22]. Phosphory-
lation of different amino acid residues may result in
changes in increased water permeability in response to
vasopressin and which is blocked by atrial natriuretic
peptide [23]. In terms of the overall level of AQP1 pro-
tein, there is some evidence that regulation of AQP1 in
the choroid plexus does occur. Spontaneously hyperten-
sive rats demonstrate increased CSF secretion and more
rapid CSF turnover [24]. This enhanced CSF secretion
Figure 5 Representative immuno-electron micrographs of choroidal epithelium in kaolin-injected hydrocephalic WT mice. A and C: low
magnification image of choroidal epithelium of hydrocephalic mice. B, D and E: Higher magnification electron micrographs corresponding to
the boxes in A and C show gold particles (white arrows) in the cytoplasm (B) and in the basal membrane of the epithelia (D and E). Mv:
microvilli; BL: basolateral membrane. (Owler et al, unpublished data).
Figure 6 Histograms representing mean ventricular areas of the wild-type (WT)(Blue) and AQP1-null mice (AQP1 KO)(Red) at 3 and 5
days post kaolin injection (dpi) compared to saline injected control (con) mice. AQP1-null control mice (n = 14) had lower ventricular
areas compared to wild-type control mice (n = 11). AQP1-null mice (n = 6 at 3 dpi; n = 11 at 5 dpi) did not demonstrate the same degree of
ventricular dilation as wild-type mice (n = 8 at 3 dpi; n = 16 at 5 dpi) at either 3 or 5 days after cisternal kaolin injection. Data are means +/-
SEM. (Owler et al, unpublished data).
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the choroid plexus. This up-regulation of choroidal
AQP1 was recently reported by Tomassoni et al.[ 2 5 ]
although the mechanism underlying this up-regulation
again remains unclear.
Dexamethasone has been found to increase expression
of AQP1 in the lungs of rats [26]. Kobayashi et al. [27]
also reported that AQP1 expression was increased by
glucocorticoid when applied to cultured brain endothe-
lial cells. However the effects of steroids on the expres-
sion of AQP1 in the choroid plexus have not yet been
tested. It does however raise an interesting question par-
ticularly in relation to steroids as an aetiology of pseu-
dotumor cerebri [28].
Degradation of AQP1 probably occurs through AQP1
ubiquitination. This refers to the post-translational mod-
ification of a protein associated with the attachment of a
small protein, ubiquitin, which labels a protein for
degradation. AQP1 ubiquitination appears to be depen-
dent on tonicity of the local cellular environment. This
was shown by Leitch et al.[ 2 9 ]w h or e p o r t e dt h a t
AQP1 ubiquitination was reduced and AQP1 half-life
increased in response to hypertonic stress in fibroblast
cell culture.
In some tissues there is evidence to suggest that
AQP1 can be regulated though translocation between
the cytoplasm and apical membrane. Page et al. [30]
described the movement of AQP1 between the cyto-
plasm and plasma membrane associated with caveolae
in rat cardiac myocytes in response to osmotic changes.
In cholangiocytes, Tietz et al. [31,32] found that AQP1
moves to the apical cell membrane from intracellular
vesicles in response to choleretic agonists to facilitate
bile secretion. Similar findings were also reported by
Marinelli et al. [33-35]. Our finding that choroidal
AQP1 is internalised after induction of hydrocephalus
secondary to kaolin injection in the mouse also supports
this notion and we speculate that this may be a form of
compensatory response to hydrocephalus.
The mechanisms underlying this translocation or traf-
ficking of AQP1 have been studied by Conner et al. [36]
in cell culture using HEK293 cells. That group con-
cluded that AQP1 trafficking was regulated by the toni-
city of the cellular environment and that this was
mediated through a protein kinase C-dependent
mechanism and that the trafficking itself was dependent
on microtubules. Further studies to determine mechan-
isms of AQP1 regulation are needed and may present
an opportunity to direct therapy.
Aquaporin 4
Location and function
AQP4 is located primarily in astrocytic end-feet, the exter-
nal and internal glial limiting membranes and the
basolateral membrane of ependymal cells [37,38] (Figure
7). Shen et al. [39] noted that the AQP4 expression was
absent in 1 day-old non hydrocephalic H-Tx rats. AQP4
expression was noted in the cerebral cortex and ependyma
at 1 week of age and then was also seen in the sub-pial
zones of the cortex, periventricular regions and the peri-
vascular foot processes of astrocytes at 4 and 8 weeks of
age. These authors suggested that this change in AQP4
expression reflected the changes in CSF circulation that
occurs in neonates.
Localisation to the end-feet of astrocytes is dependent
on interaction with the dystrophin complex including
alpha-syntrophin [40]. Its primary role appears to be in
regulating the distribution of water through the brain. It
is co-localised with the inwardly-rectified potassium
channel, Kir4.1. It is thus important in the spatial buf-
fering of potassium and therefore neuronal excitability.
Binder et al.[ 4 1 ]r e p o r t e dA Q P 4 - n u l lm i c eh a da n
increased seizure threshold compared to wild-type mice.
In contrast, seizures were more severe in alpha-syntro-
phin-deficient mice in which AQP4 is no longer concen-
trated in the astrocyte end-feet [42].
There has been some argument regarding the impor-
t a n c eo fA Q P 4i nm a i n t a i n i n gi n t e g r i t yo ft h eb l o o d -
brain barrier (BBB). Nicchia et al. [43] questioned the
role of AQP4 in maintaining the BBB after studying
mdx mice with a marked reduction in dystrophin
expression, which is important for AQP4 localisation to
the astrocyte end-feet. Zhou et al. [44] reported marked
abnormalities of the blood brain barrier in AQP4-null
mice as well as other abnormalities such as altered
astrocyte GFAP expression. Saadoun et al.[ 4 5 ]u s i n ga
variety of techniques in AQP4 -mice concluded that
there were no structural alterations of the brain due to
AQP4 deletion including the BBB. Several previous pub-
lications of the same group also suggested no alteration
of the BBB of AQP4 mice from that lab [46-48].The
latter group also examined the BBB of the Nanjing
AQP4-null mice of the type used in the study of Zhou
et al. and again found no alterations in the BBB.
A number of technical artefacts were suggested as being
responsible for the reported disruption of the BBB in
the report of Zhou et al.
AQP4 is the most abundant and widespread aqua-
p o r i ni nt h eb r a i na n do c c u r si nas h o r ti s o f o r m( 3 0 1
amino acids; M23) and a long isoform (323 amino acids;
M1)[49]. AQP4 forms heterotetramers and is a compo-
nent of orthogonal arrays of particles (OAPs) [38].
These OAPs are intramembrane structures visible on
freeze-fracture preparations. The AQP4 M23 isoform
promotes formation of OAPs in contrast to AQP4 M1
isoform which does not form OAPs without AQP4
M23. The ratio of AQP4 M23: AQP4 M1 isoforms will
therefore influence the formation of OAPs, and as OAPs
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influence AQP4 function [50-52].
The role of AQP4 in handling brain water and there-
fore brain oedema has been demonstrated in several
pathologies including cerebral tumours, traumatic brain
injury, cerebral ischaemia or stroke and brain abscess
[53]. In AQP4-null mice, after induction of conditions
in which vasogenic oedema forms such as around cere-
bral tumours and in traumatic brain injury [47], there is
increased brain oedema. However, in other conditions
such as cerebral ischaemia where cytotoxic oedema
predominates, AQP4-null mice demonstrate a reduction
in brain oedema [46]. AQP4 is also upregulated by con-
ditions that induce oedema such as cerebral tumours
[54,55] or cerebral infarction [56]. There is a report of
AQP4 staining in the choroid plexus epithelium of rats
although staining was diffuse throughout the cytoplasm
and not detected on the apical or basolateral mem-
branes. The significance of this finding is not clear [57].
AQP4 in hydrocephalus
There are some conflicting reports in the AQP4-null
phenotype in relation to ventricular size and CSF
dynamics. Manley et al. [46] reported no difference in
the brains of AQP4-null and wild-type mice, in addition
intracranial pressure and compliance were unaltered.
However, Li et al. [58] reported that the majority of
AQP4-null mice demonstrated smaller ventricular sizes,
reduced CSF production and increased brain water con-
tent compared to wild-type mice. These authors also
concluded that AQP4 was important in maintaining the
ependymal integrity in mice. Akin to the debate regard-
ing the AQP4 and the BBB, Saadoun et al. [45] reported
no changes in ventricular volume or anatomical features
of these AQP4-null mice both from the San Francisco
and Nanjing laboratories.
The main role of AQP4 in hydrocephalus appears to
be as a compensatory mechanism. Mao et al.[ 1 7 ]
reported an increased AQP4 mRNA in rats 4 weeks and
9 months after induction of hydrocephalus secondary to
kaolin injection although no differences in AQP4 pro-
tein could be detected by Western blot analysis. Shen et
al. [39] found that AQP4 expression was markedly
increased in 8 week-old H-Tx rats with spontaneously
arrested hydrocephalus compared to non-hydrocephalic
H-Tx rats. The authors suggested that the increase in
AQP4 reflected the development of a compensatory/
alternative pathway for CSF resorption as is thought to
occur in arrested hydrocephalus.
Using a communicating model of hydrocephalus sec-
ondary to subarachnoid inflammation after intrapar-
enchymal injection of L-a-lysophosphatidylcholine
(LPC) stearoyl, Tourdias et al.[ 5 9 ]a l s or e p o r t e d
increased expression of AQP4 using quantitative
Figure 7 Aquaporin-4 protein expression in mouse model of hydrocephalus. Aquaporin-4 immunostaining of AQP4
+/+ control mouse (A),
AQP4
+/+ (B), and AQP4
-/- (C) mice 5 days after kaolin injection. Asterisks indicate lateral ventricle, white arrowheads indicate ventricular
ependyma. (D) Immunoblot of AQP4 protein expression in AQP4
+/+ and AQP4
-/- control mice and AQP4
+/+ mice at 5 days after kaolin injection.
Scale bar = 100 μm. Reprinted with permission from [60].
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appeared confined to astrocytic end-feet but at later
time points astrocytes became hypertrophied and
AQP4 expression appeared throughout the extent of
the plasma membrane. Using magnetic resonance dif-
fusion-weighted imaging, the degree of experimental
hydrocephalus was correlated with up-regulation of
AQP4 and the periventricular apparent diffusion co-
efficient. The authors concluded that the pattern of
AQP4 expression was consistent with an adaptive
response to the hydrocephalus.
The finding of increased AQP4 expression in various
models of hydrocephalus has been interpreted as a com-
pensatory mechanism to allow for transependymal/
parenchymal CSF absorption. Such adaption may be a
mechanism that allows for the development of compen-
sated or arrested hydrocephalus. This hypothesis was
tested by Bloch et al. [60] who studied the development
of hydrocephalus after cisternal kaolin injection in
AQP4-null mice (Figure 7). The degree of ventricular
dilation and intracranial pressure change were both
significantly greater in AQP4 knockout mice compared
to wild-type mice at 3 and 5 days after kaolin injection.
Furthermore there was a 2-3% increase in brain par-
enchymal water content in both wild-type and AQP4-
null mice at 3 days post-injection compared to baseline,
although there was no difference between wild-type and
AQP4-null mice. This increase was interpreted as evi-
dence that hydrocephalus caused an increase in intra-
parenchymal water. These authors also discussed the
relative importance of astrocytic versus ependymal
AQP4 in hydrocephalus. According to their modelling,
AQP4 associated with the astrocytic end feet was more
important than that associated with the ependyma.
It should be noted that the ependyma is frequently
disrupted in hydrocephalus, particularly in the frontal
and occipital horns where shear strains are greatest [61].
Spontaneous hydrocephalus in AQP4-null mice
There is a small but consistent rate of spontaneous
hydrocephalus in AQP4-null mice that has been
reported by several groups. Feng et al. [48] reported a
9.6% incidence of spontaneous hydrocephalus secondary
to aqueduct stenosis. The hydrocephalus was severe
with raised intracranial pressure resulting in death
within six weeks. Li et al. [58]found that in a minority
of AQP4-null mice (7%) the aqueduct was narrowed
and there was enlargement of the lateral ventricles in
contrast to the other 93% that they reported to have
small lateral ventricles in comparison to wild-type mice
(see above).
According to Feng et al. [48], mice that had devel-
oped hydrocephalus secondary to aqueduct stenosis
displayed marked disorganisation of the ependyma at
the aqueduct. Similar findings were reported by Li
et al. [58]. Regional ependymal disorganisation was
also seen in some non-hydrocephalic mice in other
areas and ependymal disorganisation was also seen in
heterozygotes. Wild-typem i c ed i s p l a y e dn os u c h
regions. Whether mutations in or absence of AQP4 in
the ependyma of hydrocephalic patients with sporadic
aqueduct stenosis have a role in pathogenesis, is yet to
be tested.
AQP4 regulation
The regulation of AQP4 may be categorised in a similar
manner to that of AQP1 and was recently reviewed by
Yukutake and Yasui [62] and previously by Gunnarson
et al. [22]. AQP4 has been considered to be insensitive
to mercury and this has been demonstrated by a num-
ber of studies [63-66]. However, Yukutake et al.[ 6 7 ]
recently demonstrated that the water permeability of
AQP4 M23 isoform was reversibly decreased in
response to mercury using AQP4 M23-proteoliposomes
in a stopped-flow analysis. The permeability of AQP4
may also be altered through phosphorylation. Phosphor-
ylation of Ser180 decreases water permeability of AQP4
[68] while phosphorylation of Ser111 increases water
permeability [69,70]). The mechanism underlying phos-
phorylation and how it relates to physiological function
is unclear at present.
There is also some evidence for regulation of the overall
level of AQP4. As for AQP1, the tonicity of cellular envir-
onment may be important for AQP4. Zeng et al. [71]
demonstrated that AQP4 was down-regulated in response
to treatment with intravenous 10% hypertonic saline in a
rat model of ischaemia. AQP4 protein levels are increased
in response to various pathological processes. In the spon-
taneously hypertensive rat, AQP4 levels were increased in
the frontal cortex, striatum and hippocampus between
4 and 6 months of age which coincides with the develop-
ment hypertension and associated pathological changes in
these animals [25]. Interestingly, Koyama and Tanaka [72]
also recently demonstrated that ET-1, a selective ETB
receptor agonist and vasoconstrictor peptide, resulted in
down-regulation of AQP4 in rat brain.
Localisation of AQP4, particularly in the astrocytic
end feet is important for function as discussed above.
A recent study suggests that trafficking of AQP4 may be
used as a regulatory mechanism for AQP4. Moeller
et al. [73] found that vasopressin results in internalisa-
tion (to the cell cytoplasm) of AQP4 in Xenopus laevis
oocytes which is mediated by the V1a receptor. This
resulted in decreased water permeability. The effect was
reduced with mutation of Ser
180; phosphorylation which
has already been reported to decrease water permeability
[68]. This phosphorylation was mediated by protein
kinase C.
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Determining the importance of AQP1 and 4 in hydroce-
phalus and CSF production would be facilitated by the
availability of a non-toxic specific AQP1 or 4 blocking
agents. Identifying such an AQP1 blocker remains a chal-
lenge [74]. It is known that AQP1 is blocked by Hg
2+ and
other mercurial compounds but these are toxic [75]. As
mentioned, AQP4 has been considered insensitive to Hg
2+
[76]. However more recently, Yukutake et al. [67] have
suggested that the water permeability of the M23 isoform
m a yb er e d u c e db yH g
2+. Tetraethylammonium (TEA)
was also suggested as an AQP1 inhibitor [77] although the
efficacy of TEA is likely to be minimal [78]. Corticoster-
oids have been reported to up-regulate AQP 1 in the rat
lung [26], sheep fetal lung [79] as well as other tissues
[80,81]. There is as yet, no evidence that steroids influence
choroidal AQP1. AQP4 expression is not altered by corti-
costeroids [74,82].
Arylsulfonamides, including acetazolamide, a carbonic
anhydrase inhibitor that is commonly used to reduce
CSF production in the management of pseudotumor
cerebri and other clinical situations, have been suggested
as pharmacological blockers of AQP1 and 4. This has
generated considerable controversy. Ma et al.[ 8 3 ]
reported that acetazolamide reduced osmotic permeabil-
ity via interaction with AQP1. Osmotic permeability was
assessed using a swelling assay of Xenopus laevis oocytes
expressing AQP1, and the same group reported similar
findings in a swelling assay using human embryonic kid-
ney (HEK292) cells expressing pEGFP/AQP1 [84]. Using
the oocyte swelling assay, Huber et al.[ 8 5 ]r e p o r t e d
that acetazolamide and several other compounds [86,87]
had some inhibitory affect on water permeability of
AQP4. The oocyte swelling assay technique has been
criticised, and using a stopped-flow light-scattering
water permeability assay and a marker dilution techni-
que Yang et al. found no evidence that acetazolamide
inhibits AQP1 or 4 [78,88]. In addition, using modifica-
tions of the Xenopus laevis oocyte osmotic permeability
assay, Sorgaard & Zeuthen [89] found no effect of aceta-
zolamide on AQP1. Recently Tanimura et al. [90] who
also used a stopped-flow analysis technique, reported a
reversible reduction in water permeability of AQP4 due
to acetazolamide. The issue appears to remain unre-
solved with Huber and colleagues [86,87,91] continuing
to argue in favour of an inhibitory effect of acetazola-
mide on AQP1 and 4.
A small inhibitory effect of bumetamide, a loop diure-
tic that blocks the Na-K-Cl co-transporter, on AQP4
water permeability [92] has lead to the development of
other related molecules based on the structure of bume-
tamide. The arylsulfonamide AqB013 which has been
reported by Yool et al. [93] to block both AQP1 and 4
is such an example although its therapeutic potential
remains to be tested.
Other therapeutic strategies for AQP1 modulation
Apart from pharmacological blockade of AQP1, there
are several other potential routes to modulation of AQP
1 expression, none of which have thus far been
explored. These include methods to increase AQP1
degradation or reduction of AQP1 expression/transcrip-
tion. Although our knowledge of the mechanisms and
pathways underlying choroidal AQP1 regulation is lack-
ing there are possible techniques that may be employed
to increase AQP1 degradation. This includes the intra-
ventricular administration of AQP1 antibodies which
could potentially result in AQP1 internalisation and
degradation, thus temporarily reducing CSF production.
Further understanding the mechanisms through which
AQP1 is internalised, as we have observed in our studies
of choroidal AQP1 in hydrocephalic mice, may provide
additional useful information to allow these pathways to
be manipulated.
Figure 8 Lentiviral-GFP localisation in choroid plexus epithelial cells in mice. Normal Quackenbush Swiss mice received intraventricular
injection of lentiviral-GFP (10
7 virus genomes in 10 μL of sterile saline) and harvested after 7 days of injection. Frozen coronal section of the
brain were incubated with rabbit GFP antibody at 4°C overnight followed by incubation of anti-rabbit Ig conjugated with Alexa 488. GFP signals
were found in the cytoplasm of some choroid epithelial cells (arrows) in lateral choroid plexus in panel A (confocal image) and C (composite of
A and B). Panel B is the phase contrast image of the same field in A. (Owler et al., unpublished data).
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potential tool for modulating AQP1 and thus CSF pro-
duction. A small interfering RNA (siRNA) against AQP1
has been used by Boassa et al. [94] to study AQP1 func-
tion in choroid plexus cell culture. The use of si or
shRNA, delivered though lentiviral or other vectors to
transfect choroid plexus epithelial cells to reduce AQP1
expression may be feasible (Figure 8) [95]. Splinter et al.
[96] has used AQP1 siRNA to reduce AQP1 expression
in isolated intrahepatic bile duct units in the rat. This
resulted in reduced water transport in these bile duct
units in response to both an osmotic challenge and a
secretory agonist. Kim et al. [97] reported that TTF-1
(thyroid transcription factor -1) increased AQP1 tran-
scription. The 5’ region of AQP1 has multiple binding
sites for TTF-1 the expression of which is also seen in
the choroid plexus. Intraventricular injection of anti-
sense TTF-1 oligodeoxynucleotide in rats resulted in a
r e d u c t i o no fA Q P 1m R N Aa n dp r o t e i ni nt h ec h o r o i d
plexus. These rats also had an increased survival com-
pared to controls after water intoxification.
Conclusions
Aquaporin 1 makes a substantial contribution to CSF
production and is a potential therapeutic target in the
management of CSF circulation disorders. Aquaporin 4
is important in brain water homoeostasis and conse-
quentially in conditions involving both cytotoxic and
vasogenic oedema. In hydrocephalus AQP4 has a pro-
tective effect by allowing resorption of transependymal
CSF into brain capillaries. There is considerable scope
for improving our understanding of aquaporins in rela-
tion to CSF physiology in health and in diseases such as
hydrocephalus. The ultimate potential of aquaporin
modulators in the management of these conditions and
others remains to be determined. Continued study of
aquaporins in hydrocephalus and other conditions is
needed.
Acknowledgements
A/Prof Brian Owler and the Kids Neurosurgical Research Unit are supported
by the Madeline Foundation for Neurosurgical Research and a grant from
the Brain Foundation. Financial support for Dr Wang’s salary and laboratory
resources were provided by grants from: Madeline Foundation for
Neurosurgical Research and the Brain Foundation. Financial support for Dr
Pitham’s salary and laboratory resources was provided by a grant from the
Neurosurgical Society of Australasia.
Author details
1Kids Neurosurgical Research Unit, Institute of Neuroscience and Muscle
Research, Kids Research Institute, Children’s Hospital at Westmead,
Hawkesbury Rd, Westmead NSW 2145, Australia.
2TY Nelson Department of
Neurology and Neurosurgery, Children’s Hospital at Westmead, Hawkesbury
Rd, Westmead NSW 2145, Australia.
3Discipline of Child Health and
Paediatrics, Children’s Hospital at Westmead Clinical School, University of
Sydney, Hawkesbury Rd, Westmead NSW 2145, Australia.
Authors’ contributions
All authors contributed to the writing of this review. All authors have read
and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 June 2010 Accepted: 22 September 2010
Published: 22 September 2010
References
1. King LS, Agre P: Pathophysiology of the aquaporin water channels. Ann
Rev Physiol 1996, 58:619-648.
2. Saboori AM, Smith BL, Agre P: Polymorphism in the Mr 32,000 Rh protein
purified from Rh(D)-positive and -negative erythrocytes. Proc Natl Acad
Sci USA 1988, 85:4042-4045.
3. Preston GM, Carroll TP, Guggino WB, Agre P: Appearance of water
channels in Xenopus oocytes expressing red cell CHIP28 protein. Science
1992, 256:385-387.
4. Nielsen S, Smith BL, Christensen EI, Agre P: Distribution of the aquaporin
CHIP in secretory and resorptive epithelia and capillary endothelia. Proc
Natl Acad Sci USA 1993, 90:7275-7279.
5. Praetorius J, Nielsen S: Distribution of sodium transporters and
aquaporin-1 in the human choroid plexus. Am J Physiol Cell Physiol 2006,
291:C59-67.
6. Johansson PA, Dziegielewska KM, Ek CJ, Habgood MD, Mollgard K, Potter A,
Schuliga M, Saunders NR: Aquaporin-1 in the choroid plexuses of
developing mammalian brain. Cell Tissue Res 2005, 322:353-364.
7. Masseguin C, LePanse S, Corman B, Verbavatz JM, Gabrion J: Aging affects
choroidal proteins involved in CSF production in Sprague-Dawley rats.
Neurobiol Aging 2005, 26:917-927.
8. Arcienega II, Brunet JF, Bloch J, Badaut J: Cell locations for AQP1, AQP4
and 9 in the non-human primate brain. Neuroscience 2010, 167:1103-1114.
9. Mylonakou MN, Petersen PH, Rinvik E, Rojek A, Valdimarsdottir E, Zelenin S,
Zeuthen T, Nielsen S, Ottersen OP, Amiry-Moghaddam M: Analysis of mice
with targeted deletion of AQP9 gene provides conclusive evidence for
expression of AQP9 in neurons. J Neurosci Res 2009, 87:1310-1322.
10. Badaut J, Petit JM, Brunet JF, Magistretti PJ, Charriaut-Marlangue C, Regli L:
Distribution of Aquaporin 9 in the adult rat brain: preferential
expression in catecholaminergic neurons and in glial cells. Neuroscience
2004, 128:27-38.
11. Badaut J, Regli L: Distribution and possible roles of aquaporin 9 in the
brain. Neuroscience 2004, 129:971-981.
12. Badaut J, Brunet JF, Petit JM, Guerin CF, Magistretti PJ, Regli L: Induction of
brain aquaporin 9 (AQP9) in catecholaminergic neurons in diabetic rats.
Brain Res 2008, 1188:17-24.
13. Owler B: CSF shunt failure: an ongoing epidemic? J Neurol Neurosurg
Psychiat 2009, 80:1185.
14. Johanson CE, Duncan JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD:
Multiplicity of cerebrospinal fluid functions: New challenges in health
and disease. Cerebrospinal Fluid Res 2008, 5:10.
15. Oshio K, Watanabe H, Song Y, Verkman AS, Manley GT, Oshio K,
Watanabe H, Song Y, Manley GT: Reduced cerebrospinal fluid production
and intracranial pressure in mice lacking choroid plexus water channel
Aquaporin-1. FASEB Journal 2005, 19:76-78.
16. Praetorius J: Water and solute secretion by the choroid plexus. Pflugers
Archiv 2007, 454:1-18.
17. Mao X, Enno TL, Del Bigio MR, Mao X, Enno TL, Del Bigio MR: Aquaporin 4
changes in rat brain with severe hydrocephalus. Eur J Neurosci 2006,
23:2929-2936.
18. Tirapelli DP, Lopes Lda S, Lachat JJ, Colli BO, Tirapelli LF, Tirapelli DPdC,
Lopes LdS, Lachat JJ, Colli BO, Tirapelli LF: Ultrastructural study of the
lateral ventricle choroid plexus in experimental hydrocephalus in Wistar
rats. Arq Neuropsiquiatr 2007, 65:974-977.
19. Longatti P, Basaldella L, Orvieto E, Dei Tos A, Martinuzzi A, Longatti P,
Basaldella L, Orvieto E, Dei Tos A, Martinuzzi A: Aquaporin(s) expression in
choroid plexus tumours. Ped Neurosurg 2006, 42:228-233.
20. Amiry-Moghaddam M, Ottersen OP: The molecular basis of water
transport in the brain. Nat Rev Neurosci 2003, 4:991-1001.
Brian et al. Cerebrospinal Fluid Research 2010, 7:15
http://www.cerebrospinalfluidresearch.com/content/7/1/15
Page 10 of 1221. Hasegawa H, Zhang R, Dohrman A, Verkman AS: Tissue-specific expression
of mRNA encoding rat kidney water channel CHIP28k by in situ
hybridization. Am J Physiol 1993, 264:C237-245.
22. Gunnarson E, Zelenina M, Aperia A: Regulation of brain aquaporins.
Neuroscience 2004, 129:947-955.
23. Patil RV, Han Z, Wax MB: Regulation of water channel activity of
aquaporin 1 by arginine vasopressin and atrial natriuretic peptide.
Biochem Biophys Res Commun 1997, 238:392-396.
24. Al-Sarraf H, Philip L: Effect of hypertension on the integrity of blood brain
and blood CSF barriers, cerebral blood flow and CSF secretion in the rat.
Brain Res 2003, 975:179-188.
25. Tomassoni D, Bramanti V, Amenta F: Expression of aquaporins 1 and 4 in
the brain of spontaneously hypertensive rats. Brain Res 2010,
1325:155-163.
26. King LS, Nielsen S, Agre P: Aquaporin-1 water channel protein in lung:
ontogeny, steroid-induced expression, and distribution in rat. J Clin Invest
1996, 97:2183-2191.
27. Kobayashi H, Yanagita T, Yokoo H, Wada A: Molecular mechanisms and
drug development in aquaporin water channel diseases: aquaporins in
the brain. J Pharmacol Sci 2004, 96:264-270.
28. Walker AE, Adamkiewicz JJ: Pseudotumor cerebri associated with
prolonged corticosteroid therapy: reports of 4 cases. JAMA 1964,
188:779-784.
29. Leitch V, Agre P, King LS: Altered ubiquitination and stability of
aquaporin-1 in hypertonic stress. Proc Natl Acad Sci USA 2001,
98:2894-2898.
30. Page E, Winterfield J, Goings G, Bastawrous A, Upshaw-Earley J: Water
channel proteins in rat cardiac myocyte caveolae: osmolarity-dependent
reversible internalization. Am J Physiol 1998, 274:H1988-2000.
31. Tietz PS, McNiven MA, Splinter PL, Huang BQ, Larusso NF, Tietz PS,
McNiven MA, Splinter PL, Huang BQ, Larusso NF: Cytoskeletal and motor
proteins facilitate trafficking of AQP1-containing vesicles in
cholangiocytes. Biol Cell 2006, 98:43-52.
32. Tietz PS, Marinelli RA, Chen XM, Huang B, Cohn J, Kole J, McNiven MA,
Alper S, LaRusso NF: Agonist-induced coordinated trafficking of
functionally related transport proteins for water and ions in
cholangiocytes. J Biol Chem 2003, 278:20413-20419.
33. Marinelli RA: Molecular mechanisms of water transport in bile formation:
aquaporin water channels. Trends Mol Med 2004, 10:584.
34. Marinelli RA, Tietz PS, Pham LD, Rueckert L, Agre P, LaRusso NF: Secretin
induces the apical insertion of aquaporin-1 water channels in rat
cholangiocytes. Am J Physiol 1999, 276:G280-286.
35. Marinelli RA, Pham L, Agre P, LaRusso NF: Secretin promotes osmotic
water transport in rat cholangiocytes by increasing aquaporin-1 water
channels in plasma membrane. Evidence for a secretin-induced vesicular
translocation of aquaporin-1. J Biol Chem 1997, 272:12984-12988.
36. Conner MT, Conner AC, Brown JE, Bill RM: Membrane trafficking of
aquaporin 1 is mediated by protein kinase C via microtubules and
regulated by tonicity. Biochemistry 2010, 49:821-823.
37. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P,
Ottersen OP: Specialized membrane domains for water transport in glial
cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat
brain. J Neurosci 1997, 17:171-180.
38. Rash JE, Yasumura T, Hudson CS, Agre P, Nielsen S: Direct immunogold
labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte
plasma membranes in rat brain and spinal cord. Proc Natl Acad Sci USA
1998, 95:11981-11986.
39. Shen XQ, Miyajima M, Ogino I, Arai H, Shen XQ, Miyajima M, Ogino I,
Arai H: Expression of the water-channel protein aquaporin 4 in the H-Tx
rat: possible compensatory role in spontaneously arrested
hydrocephalus. [see comment]. J Neurosurg 2006, 105:459-464.
40. Amiry-Moghaddam M, Frydenlund DS, Ottersen OP: Anchoring of
aquaporin-4 in brain: molecular mechanisms and implications for the
physiology and pathophysiology of water transport. Neuroscience 2004,
129:999-1010.
41. Binder DK, Oshio K, Ma T, Verkman AS, Manley GT, Binder DK, Oshio K,
Ma T, Manley GT: Increased seizure threshold in mice lacking aquaporin-
4 water channels. Neuroreport 2004, 15:259-262.
42. Amiry-Moghaddam M, Williamson A, Palomba M, Eid T, de Lanerolle NC,
Nagelhus EA, Adams ME, Froehner SC, Agre P, Ottersen OP: Delayed K+
clearance associated with aquaporin-4 mislocalization: phenotypic
defects in brains of alpha-syntrophin-null mice. Proc Natl Acad Sci USA
2003, 100:13615-13620.
43. Nicchia GP, Nico B, Camassa LM, Mola MG, Loh N, Dermietzel R, Spray DC,
Svelto M, Frigeri A: The role of aquaporin-4 in the blood-brain barrier
development and integrity: studies in animal and cell culture models.
Neuroscience 2004, 129:935-945.
44. Zhou J, Kong H, Hua X, Xiao M, Ding J, Hu G: Altered blood-brain barrier
integrity in adult aquaporin-4 knockout mice. Neuroreport 2008, 19:1-5.
45. Saadoun S, Tait MJ, Reza A, Davies DC, Bell BA, Verkman AS,
Papadopoulos MC: AQP4 gene deletion in mice does not alter blood-
brain barrier integrity or brain morphology. Neuroscience 2009,
161:764-772.
46. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, Chan P,
Verkman AS: Aquaporin-4 deletion in mice reduces brain edema after
acute water intoxication and ischemic stroke. Nat Med 2000, 6:159-163.
47. Papadopoulos MC, Manley GT, Krishna S, Verkman AS, Papadopoulos MC,
Manley GT, Krishna S: Aquaporin-4 facilitates reabsorption of excess fluid
in vasogenic brain edema. FASEB Journal 2004, 18:1291-1293.
48. Feng X, Papadopoulos MC, Liu J, Li L, Zhang D, Zhang H, Verkman AS,
Ma T, Feng X, Papadopoulos MC, Liu J, Li L, Zhang D, Zhang H, Ma T:
Sporadic obstructive hydrocephalus in Aqp4 null mice. J Neurosci Res
2009, 87:1150-1155.
49. Neely JD, Christensen BM, Nielsen S, Agre P: Heterotetrameric composition
of aquaporin-4 water channels. Biochemistry 1999, 38:11156-11163.
50. Hiroaki Y, Tani K, Kamegawa A, Gyobu N, Nishikawa K, Suzuki H, Walz T,
Sasaki S, Mitsuoka K, Kimura K, Mizoguchi A, Fujiyoshi Y: Implications of the
aquaporin-4 structure on array formation and cell adhesion. J Mol Biol
2006, 355:628-639.
51. Furman CS, Gorelick-Feldman DA, Davidson KG, Yasumura T, Neely JD,
Agre P, Rash JE: Aquaporin-4 square array assembly: opposing actions of
M1 and M23 isoforms. Proc Natl Acad Sci USA 2003, 100:13609-13614.
52. Crane JM, Verkman AS: Determinants of aquaporin-4 assembly in
orthogonal arrays revealed by live-cell single-molecule fluorescence
imaging. J Cell Sci 2009, 122:813-821.
53. Papadopoulos MC, Verkman AS, Papadopoulos MC, Verkman AS:
Aquaporin-4 and brain edema. Ped Nephrol 2007, 22:778-784.
54. Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S,
Verkman AS: Molecular mechanisms of brain tumor edema. Neuroscience
2004, 129:1011-1020.
55. Saadoun S, Papadopoulos MC, Davies DC, Bell BA, Krishna S: Increased
aquaporin 1 water channel expression in human brain tumours. BJ
Cancer 2002, 87:621-623.
56. Aoki K, Uchihara T, Tsuchiya K, Nakamura A, Ikeda K, Wakayama Y:
Enhanced expression of aquaporin 4 in human brain with infarction.
Acta Neuropathol 2003, 106:121-124.
57. Speake T, Freeman LJ, Brown PD: Expression of aquaporin 1 and
aquaporin 4 water channels in rat choroid plexus. Biochim Biophys Acta
2003, 1609:80-86.
58. Li X, Kong H, Wu W, Xiao M, Sun X, Hu G: Aquaporin-4 maintains
ependymal integrity in adult mice. Neuroscience 2009, 162:67-77.
59. Tourdias T, Dragonu I, Fushimi Y, Deloire MS, Boiziau C, Brochet B,
Moonen C, Petry KG, Dousset V: Aquaporin 4 correlates with apparent
diffusion coefficient and hydrocephalus severity in the rat brain: a
combined MRI-histological study. Neuroimage 2009, 47:659-666.
60. Bloch O, Auguste KI, Manley GT, Verkman AS: Accelerated progression of
kaolin-induced hydrocephalus in aquaporin-4-deficient mice. J Cereb
Blood Flow Metab 2006, 26:1527-1537.
61. Pena A, Harris NG, Bolton MD, Czosnyka M, Pickard JD: Communicating
hydrocephalus: the biomechanics of progressive ventricular enlargement
revisited. Acta Neurochir Suppl 2002, 81:59-63.
62. Yukutake Y, Yasui M: Regulation of water permeability through
aquaporin-4. Neuroscience 2010, 168:885-891.
63. Shi LB, Verkman AS: Selected cysteine point mutations confer mercurial
sensitivity to the mercurial-insensitive water channel MIWC/AQP-4.
Biochemistry 1996, 35:538-544.
64. Nicchia GP, Frigeri A, Liuzzi GM, Santacroce MP, Nico B, Procino G,
Quondamatteo F, Herken R, Roncali L, Svelto M: Aquaporin-4-containing
astrocytes sustain a temperature- and mercury-insensitive swelling in
vitro. Glia 2000, 31:29-38.
65. Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P: Molecular
characterization of an aquaporin cDNA from brain: candidate
Brian et al. Cerebrospinal Fluid Research 2010, 7:15
http://www.cerebrospinalfluidresearch.com/content/7/1/15
Page 11 of 12osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA
1994, 91:13052-13056.
66. Jung JS, Preston GM, Smith BL, Guggino WB, Agre P: Molecular structure
of the water channel through aquaporin CHIP. The hourglass model. J
Biol Chem 1994, 269:14648-14654.
67. Yukutake Y, Tsuji S, Hirano Y, Adachi T, Takahashi T, Fujihara K, Agre P,
Yasui M, Suematsu M: Mercury chloride decreases the water permeability
of aquaporin-4-reconstituted proteoliposomes. Biol Cell 2008, 100:355-363.
68. Zelenina M, Zelenin S, Bondar AA, Brismar H, Aperia A: Water permeability
of aquaporin-4 is decreased by protein kinase C and dopamine. Am J
Physiol Renal Physiol 2002, 283:F309-318.
69. Gunnarson E, Axehult G, Baturina G, Zelenin S, Zelenina M, Aperia A: Lead
induces increased water permeability in astrocytes expressing aquaporin
4. Neuroscience 2005, 136:105-114.
70. Gunnarson E, Zelenina M, Axehult G, Song Y, Bondar A, Krieger P,
Brismar H, Zelenin S, Aperia A: Identification of a molecular target for
glutamate regulation of astrocyte water permeability. Glia 2008,
56:587-596.
71. Zeng HK, Wang QS, Deng YY, Fang M, Chen CB, Fu YH, Jiang WQ, Jiang X:
Hypertonic saline ameliorates cerebral edema through downregulation
of aquaporin-4 expression in the astrocytes. Neuroscience 2010,
166:878-885.
72. Koyama Y, Tanaka K: Decreases in rat brain aquaporin-4 expression
following intracerebroventricular administration of an endothelin ET B
receptor agonist. Neurosci Lett 2010, 469:343-347.
73. Moeller HB, Fenton RA, Zeuthen T, Macaulay N: Vasopressin-dependent
short-term regulation of aquaporin 4 expressed in Xenopus oocytes.
Neuroscience 2009, 164:1674-1684.
74. Papadopoulos MC, Verkman AS, Papadopoulos MC: Potential utility of
aquaporin modulators for therapy of brain disorders. Prog Brain Res 2008,
170:589-601.
75. Niemietz CM, Tyerman SD: New potent inhibitors of aquaporins: silver
and gold compounds inhibit aquaporins of plant and human origin.
FEBS Lett 2002, 531:443-447.
76. Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: Generation
and phenotype of a transgenic knockout mouse lacking the mercurial-
insensitive water channel aquaporin-4. J Clin Invest 1997, 100:957-962.
77. Brooks HL, Regan JW, Yool AJ: Inhibition of aquaporin-1 water
permeability by tetraethylammonium: involvement of the loop E pore
region. Mol Pharmacol 2000, 57:1021-1026.
78. Yang B, Kim JK, Verkman AS: Comparative efficacy of HgCl2 with
candidate aquaporin-1 inhibitors DMSO, gold, TEA+ and acetazolamide.
FEBS Lett 2006, 580:6679-6684.
79. Liu H, Hooper SB, Armugam A, Dawson N, Ferraro T, Jeyaseelan K, Thiel A,
Koukoulas I, Wintour EM: Aquaporin gene expression and regulation in
the ovine fetal lung. J Physiol 2003, 551:503-514.
80. Stoenoiu MS, Ni J, Verkaeren C, Debaix H, Jonas JC, Lameire N,
Verbavatz JM, Devuyst O: Corticosteroids induce expression of aquaporin-
1 and increase transcellular water transport in rat peritoneum. JA mS o c
Nephrol 2003, 14:555-565.
81. Moon C, King LS, Agre P: Aqp1 expression in erythroleukemia cells:
genetic regulation of glucocorticoid and chemical induction. Am J Physiol
1997, 273:C1562-1570.
82. Gu F, Hata R, Toku K, Yang L, Ma YJ, Maeda N, Sakanaka M, Tanaka J:
Testosterone up-regulates aquaporin-4 expression in cultured astrocytes.
J Neurosci Res 2003, 72:709-715.
83. Ma B, Xiang Y, Mu SM, Li T, Yu HM, Li XJ: Effects of acetazolamide and
anordiol on osmotic water permeability in AQP1-cRNA injected Xenopus
oocyte. Acta Pharmacol Sin 2004, 25:90-97.
84. Gao J, Wang X, Chang Y, Zhang J, Song Q, Yu H, Li X: Acetazolamide
inhibits osmotic water permeability by interaction with aquaporin-1.
Anal Biochem 2006, 350:165-170.
85. Huber VJ, Tsujita M, Yamazaki M, Sakimura K, Nakada T: Identification of
arylsulfonamides as Aquaporin 4 inhibitors. Bioorg Med Chem Lett 2007,
17:1270-1273.
86. Huber VJ, Tsujita M, Kwee IL, Nakada T: Inhibition of aquaporin 4 by
antiepileptic drugs. Bioorg Med Chem 2009, 17:418-424.
87. Huber VJ, Tsujita M, Nakada T: Identification of aquaporin 4 inhibitors
using in vitro and in silico methods. Bioorg Med Chem 2009, 17:411-417.
88. Yang B, Zhang H, Verkman AS: Lack of aquaporin-4 water transport
inhibition by antiepileptics and arylsulfonamides. Bioorg Med Chem 2008,
16:7489-7493.
89. Sogaard R, Zeuthen T: Test of blockers of AQP1 water permeability by a
high-resolution method: no effects of tetraethylammonium ions or
acetazolamide. Pflug Arch 2008, 456:285-292.
90. Tanimura Y, Hiroaki Y, Fujiyoshi Y: Acetazolamide reversibly inhibits water
conduction by aquaporin-4. J Struct Biol 2009, 166:16-21.
91. Huber VJ: Support for small molecule inhibition of aquaporin 4. Bioorg
Med Chem 2009, 17:425-426.
92. Migliati E, Meurice N, DuBois P, Fang JS, Somasekharan S, Beckett E,
Flynn G, Yool AJ: Inhibition of aquaporin-1 and aquaporin-4 water
permeability by a derivative of the loop diuretic bumetanide acting at
an internal pore-occluding binding site. Mol Pharmacol 2009, 76:105-112.
93. Yool AJ, Brown EA, Flynn GA: Roles for novel pharmacological blockers of
aquaporins in the treatment of brain oedema and cancer. Clin Exp
Pharmacol Physiol 2009, 37(4):403-9.
94. Boassa D, Stamer WD, Yool AJ: Ion channel function of aquaporin-1
natively expressed in choroid plexus. J Neurosci 2006, 26:7811-7819.
95. Alexander IE, Russell DW, Spence AM, Miller AD: Effects of gamma
irradiation on the transduction of dividing and nondividing cells in brain
and muscle of rats by adeno-associated virus vectors. Hum Gene Ther
1996, 7:841-850.
96. Splinter PL, Masyuk AI, LaRusso NF: Specific inhibition of AQP1 water
channels in isolated rat intrahepatic bile duct units by small interfering
RNAs. J Biol Chem 2003, 278:6268-6274.
97. Kim JG, Son YJ, Yun CH, Kim YI, Nam-Goong IS, Park JH, Park SK, Ojeda SR,
D’Elia AV, Damante G, Lee BJ: Thyroid transcription factor-1 facilitates
cerebrospinal fluid formation by regulating aquaporin-1 synthesis in the
brain. J Biol Chem 2007, 282:14923-14931.
doi:10.1186/1743-8454-7-15
Cite this article as: Brian et al.: Aquaporins: relevance to cerebrospinal
fluid physiology and therapeutic potential in hydrocephalus.
Cerebrospinal Fluid Research 2010 7:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Brian et al. Cerebrospinal Fluid Research 2010, 7:15
http://www.cerebrospinalfluidresearch.com/content/7/1/15
Page 12 of 12